Supplements and Featured Publications, Facing Type 2 Diabetes in the Healthcare Reform Era [CME/CPE], Volume 16, Issue 11 Suppl

Faculty Affiliations: From MedImpact Healthcare Systems, Inc, San Diego, CA (LLB); Division of Endocrinology, Cedars-Sinai Medical Center and David Geffen School of Medicine, UCLA, Los Angeles, CA (MAB); Washington State University College of Pharmacy, Pullman, WA (RKC); Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL (AD); Johns Hopkins HealthCare, Glen Burnie, MD (HF); University of Michigan Center for Value-Based Insurance Design, Ann Arbor, MI (AMF); University of Maryland School of Medicine and Center for Preventive Cardiology, University of Maryland Hospital, Baltimore, MD (MM); Priority Health, Bloomfield Hills, MI (BN); Boston Medical Center and Boston University School of Medicine, Boston, MA (JLR); Department of Medicine, Division of Diabetes, UTHSCSA Texas Diabetes Institute, San Antonio, TX (CT); DoctorLearns, LLC, Merchantville, NJ (WJY).

Funding Source: This activity was supported by an educational grant from Amylin Pharmaceuticals, Inc and Lilly USA, LLC.

Faculty Disclosures: Dr Brunetti reports receiving honoraria from Amylin; Pfizer; sanofi-aventis; and Takeda. Dr Bush reports being a member of the speakers' bureau for AstraZeneca; Bristol-Myers Squibb; Lilly; Merck; and Novo Nordisk, and meeting/conference attendance for Novo Nordisk and Merck. Mr Campbell reports receiving honoraria from Lilly. Dr Fendrick reports being a consultant for Abbott Laboratories; ActiveHealth Management, Inc; AstraZeneca; Avalere Health LLC; Blue Cross and Blue Shield Association; GlaxoSmithKline; Hewitt Associates LLC; MedImpact HeathCare Systems, Inc; Perrigo; Pfizer; The Regence Group; sanofi-aventis U.S. LLC; WebMD, LLC; and UCB, Inc. He also reports that he is a speaker for Merck; Pfizer; and sanofiaventis U.S. LLC, and receives research support from Abbott Laboratories; AstraZeneca; Lilly; GlaxoSmithKline; Merck; Novartis Corporation; Pfizer; and sanofi-aventis U.S. LLC. Dr Rosenzweig reports being a member of the scientific advisory board for Alere, LLC. Dr Triplitt reports being a consultant for Roche and Takeda, and receiving honoraria from Amylin, Lilly, and Roche. Drs Dunaif, Miller, and Niebylski, and Mr Fatodu and Mr Yarnall report no relationship or financial interest with any entity that would pose a conflict of interest with the subject matter of this supplement.

Faculty Information: Concept and design (LLB, MAB, RKC, AD, HF, AMF, BN, CT); acquisition of data (MAB, AMF, BN); analysis and interpretation of data (LLB, MAB, RKC, AD, AMF, MM, BN, JLR, CT, WJY); drafting of the manuscript (WJY); critical revision of the manuscript for important intellectual content (LLB, MAB, RKC, AD, HF, AMF, MM, BN, JLR, CT); administrative, technical, or logistic support (WJY); supervision (MM, JLR); and other (HF [roundtable participation]).

Address correspondence to: A. Mark Fendrick, MD, University of Michigan Center for Value-Based Insurance Design, 300 North Ingalls, Suite 7E06, Ann Arbor, MI 48109. E-mail: amfen@med.umich.edu.